References
1. Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. In:
Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization
classification of tumors. Pathology and genetics of tumors of soft
tissue and bone. Lyon: IARC Press, 2002:91–3.
2. Panagiotopoulos N, Patrini D, Gvinianidze L, et al. Inflammatory
myofibroblastic tumor of the lung: a reactive lesion or a true neoplasm?
Thorac Dis 2015; 7: 908–11.
3. Dalton BG, Thomas PG, Sharp NE, et al. Inflammatory myofibroblastic
tumors in children. J Pediatr Surg. 2016 Apr;51(4):541-4. doi:
10.1016/j.jpedsurg.2015.11.015.
4. Muñoz Moya JE, Alfaro Aguirre MO, Leiva Silva M, Kakarieka Weisskopf
E, López Sáez MT. Tumor miofibroblástico inflamatorio: Presentación
variable de una misma patología [Inflammatory myofibroblastic tumor:
Variable presentation of the same pathology]. Rev Chil Pediatr.
2019;90(3):328-335.
5. Mossé YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib
for pediatric patients with refractory solid tumors or anaplastic
large-cell lymphoma: a Children’s Oncology Group phase 1 consortium
study. Lancet Oncol. 2013;14(6):472-480.
doi:10.1016/S1470-2045(13)70095-0
6. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumors: where
are we now? J Clin Pathol 2008; 61:428–37.
7. Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and
chromosomal rearrangements involving 2p23 in an inflammatory
myofibroblastic tumor. Mod Pathol 2001; 14:569–76.
8. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of
2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;
59:2776–80.
9. Fu GX, Xu CC, Yao NF, Gu JZ, Jiang HL, Han XF. Inflammatory
myofibroblastic tumor: A demographic, clinical, and therapeutic study of
92 cases. Math Biosci Eng. 2019;16(6):6794-6804. doi:10.3934/mbe.2019339
10. Shetty SJ, Pereira T, Desai RS. Inflammatory myofibroblastic tumor
of the oral cavity: A case report and literature review. J Cancer Res
Ther. 2019;15(3):725-728. doi:10.4103/jcrt.JCRT_1044_16
11. Maruyama Y, Fukushima T, Gomi D, et al. Relapsed and unresectable
inflammatory myofibroblastic tumor responded to chemotherapy: A case
report and review of the literature. Mol Clin Oncol. 2017;7(4):521-524.
doi:10.3892/mco.2017.1383
12. Tao YL, Wang ZJ, Han JG, et al. Inflammatory myofibroblastic tumor
successfully treated with chemotherapy and non-steroidal: A case report:
World J Gastroenterol. 2012;18: 7100-7103.
13. Kusunoki-Nakamoto F, Matsukawa T, Tanaka M, et al. Successful
treatment of an unresectable inflammatory myofibroblastic tumor of the
frontal bone using a cyclooxygenase-2 inhibitor and methotrexate. Intern
Med. 2013; 52: 623-628.
14. Applebaum H, Kieran MW, Cripe TP, et al. The rationale for
non-steroidal anti-inflammatory drug therapy for inflammatory
myofibroblastic tumors: a Children’s Oncology Group study. J Pediatr
Surg. 2005; 40: 999 –1003.
15. Theilen TM, Soerensen J, Bochennek K, et al. Crizotinib in ALK+
inflammatory myofibroblastic tumors-Current experience and future
perspectives. Pediatr Blood Cancer. 2018;65(4):10.1002/pbc.26920.
doi:10.1002/pbc.26920
16. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in
Pediatric Anaplastic Large Cell Lymphoma and Inflammatory
Myofibroblastic Tumor: A Children’s Oncology Group Study. J Clin Oncol.
2017;35(28):3215-3221. doi:10.1200/JCO.2017.73.4830
17. Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H.
Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with
ALK mutation. Intern Med. 2019;58(7):1029-1032.
doi:10.2169/internalmedicine.1640-18